Larimar Therapeutics, Inc. (LRMR) stock analysis
In our weekly check, Larimar Therapeutics, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 10.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LRMR.
What our checks show for LRMR
Red flags
- Weak EPS forecast
- Analysts expect the net margin to shrink by 104 points from today's 0%.
- Weak EPS growth
- The company has no revenue yet.
- Free cash flow is negative and the company has no revenue yet: it lives on its cash and new funding.
- The price swings a lot: 88.5% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 100% from a peak. Would you have held through that?
- The share count grew by 66.2% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- A small company (market value $314 million): usually riskier and followed by fewer analysts.
- The stock is still below its previous peak.
Strengths
- Debt is low: 0.04x equity.
- Beta 0.69: the stock usually moves less than the market.
Similar companies
KYTX · BNTC · MPLT · XFOR · ALT · PEPG
Questions
What grade does Larimar Therapeutics, Inc. (LRMR) have?
In our weekly check, Larimar Therapeutics, Inc. is graded F (A to F). Of 18 checks on debt, profit, cash flow and trend: 5 pass, warnings: 3, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of LRMR stock?
This week's biggest flags for Larimar Therapeutics, Inc.: Weak EPS forecast, Margins expected to shrink, Weak EPS growth. In total 13 of 18 checks show a warning or a red flag.
What does Larimar Therapeutics, Inc. do?
Larimar Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LRMR.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis